The two sides of ADAM17 in inflammation: Implications in atherosclerosis and obesity;Les deux visages d'ADAM17 dans l'inflammation: Implications dans l'athérosclérose et l'obésité

Medecine/Sciences

Volumn 25, Issue 1, 2009, Pages 45-50

  Peiretti, Franck ^a   Canault, Matthias ^a   Morange, Pierre ^a   Alessi, Marie Christine ^a   Nalbone, Gilles ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MUS;

EID: 58849114199     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200925145     Document Type: Review

References (43)

1. Mezyk R, Bzowska M, Bereta J. Structure and functions of tumor necrosis factor-aipha converting enzyme. Acta Biochim Pol 2003 ; 50 : 625-45.
2. Huovila APJ, Turner AJ, Pelto-Huikko M, et al. Shedding light on ADAM metalloproteinases. Trends Biochem Sci 2005 ; 30 : 413-22.
3. Blobel CP. ADAMS : key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005 ; 6 : 32-43.
4. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008 ; 29 : 258-89.
5. Alfandari D, Cousin H, Gaultier A, Darribère T. Les protéines de la famille ADAM : protéolyse, adhérence et signalisation. Med Sci (Paris) 1999 ; 15 : 1148-51.
6. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour necrosis factor-alpha from cells. Nature 1997 ; 385 : 729-33.
7. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997 ; 385 : 733-6.
8. Peiretti F, Deprez-Beauclair P, Bonardo B, et al. Identification of SAP97 as an intracellular binding partner of TACE. J Cell Sci 2003 ; 116 : 1949-57.
9. Canault M, Tellier E, Bonardo B, et al. FHL2 interacts with both ADAM-17 and the cytoskeleton and regulates ADAM-17 localization and activity. J Cell Physiol 2006 ; 208 : 363-72.
10. Soond SM, Everson B, Riches DWH, Murphy G. ERK-mediated phosphorylation of Thr735 in TNF(alpha)-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci 2005 ; 118 : 2371-80.
11. Milla ME, Gonzales PE, Leonard JD. The TACE zymogen : re-examining the role of the cysteine switch. Cell Biochem Btophys 2006 ; 44 : 342-8.
12. Peiretti F, Canault M, Deprez-Beauclair P, et al. Intracellular maturation and transport of tumor necrosis factor alpha converting enzyme. Exp Cell Res 2003 ; 285 : 278-85.
13. Sagi I, Milla ME. Application of structural dynamic approaches provide novel insights into the enzymatic mechanism of the tumor necrosis factor-(alpha)-converting enzyme. Anal Biochem 2008 ; 372 : 1-10.
14. Amour A, Slocombe PM, Webster A, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998 ; 435 : 39-44.
15. Matthews V, Schuster B, Schutze S, et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003 ; 278 : 38829-39.
16. Tellier E, Canault M, Rebsomen L, et al. The shedding activity of ADAM17 is sequestered in lipid rafts. Exp Cell Res 2006 ; 312 : 3969-80.
17. Eissner G, Kolch W, Scheurich P. Ligands working as receptors : reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004 ; 15 : 353-66.
18. Horiuchi K, Kimura T, Miyamoto T, et al. Cutting edge : TNF-(alpha)-converting enzyme (TACE/ ADAM17) inactivation in mouse myeloid celts prevents lethality from endotoxin shock. J Immunol 2007 ; 179 : 2686-9.
19. Li N, Boyd K, Dempsey PJ, Vignoli DAA. N on-cell autonomous expression of TNF-(alpha)-converting enzyme ADAM17 is required for normal lymphocyte development. J Immunol 2007 ; 178 : 4214-21.
20. Akassoglou K, Probert L, Kontogeorgos G, Kollias G. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 1997 ; 158 : 438-45.
21. Mueller C, Corazza N, Trachsel-Loseth S, et al. Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNF alpha) mediates effects distinct from those of wild-type TNF alpha in vitro and in vivo. J Biol Chem 1999 ; 274 : 38112-8.
22. Olleros ML, Guler R, Corazza N, et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-(alpha). J Immunol 2002 ; 168 : 3394-401.
23. Voros G, Maquoi E, Collen D, Lijnen HR. Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-(alpha), TNF-(alpha) converting enzyme and ADAMTS family members in murine fat territories. Biochim Biophys Acta 2003 ; 1625 : 36-42.
24. Smookler DS, Mohammed FF, Kassiri Z, et al. Cutting edge : tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol 2006 ; 176 : 721-5.
25. Tang Zy, Loss G, Carmody I, Cohen AJ. TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats. Transplantation 2006 ; 82 : 1518-23.
26. Purcell MK, Mu JL, Higgins DC, et al. Fine mapping of Ath6, a quantitative trait locus for atherosclerosis in mice. Mamm Genome 2001 ; 12 : 495-500.
27. Holdt LM, Thiery J, Breslow JL, Teupser D. Increased ADAM17 mRNA expression and activity is associated with atherosclerosis resistance in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol 2008 ; 28 : 1097-103.
28. Canault M, Peiretti F, Kopp F, et al. The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice : possible contribution to elevated plasma levels of soluble TNF alpha receptors. Atherosclerosis 2006 ; 187 : 82-91.
29. Canault M, Leroyer AS, Peiretti F, et al. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-(alpha) converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol 2007 ; 171 : 1713-23.
30. Canault M, Peiretti F, Poggi M, et al. Progression of atherosclerosis in ApoE-deficient mice that express distinct molecular forms of TNF-alpha. J Pathol 2008 ; 214 : 574-83.
31. Fedak PWM, Moravec CS, McCarthy PM, et al. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation 2006 ; 113 : 238-45.
32. Shimoda Y, Satoh M, Nakamura M, et al. Activated tumour necrosis factor-alpha shedding process is associated with in-hospital complication in patients with acute myocardial infarction. Clin Sci (Lond) 2005 ; 108 : 339-47.
33. Morange P, Tregouet D, Godefroy T, et al. Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ ADAM17) genes in relation to cardiovascular mortality : the Athero Gene study. J Mol Med 2008 ; 86 : 1153-61.
34. Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 2000 ; 32 (suppl 1) : 78-84.
35. Xu H, Uysal KT, Becherer JD, et al. Altered tumor necrosis factor-(alpha) (TNF-[alpha]) processing in adipocytes and increased expression of transmembrane TNF-(alpha) in obesity. Diabetes 2002 ; 51 : 1876-83.
36. Xu H, Hirosumi J, Uysal KT, et al. Exclusive action of transmembrane TNF(alpha) in adipose tissue leads to reduced adipose mass and local but not systemic insulin resistance. Endocrinology 2002 ; 143 : 1502-11.
37. Lee K, Villena JA, Moon YS, et al. Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1 (Pref-1). J Clin Invest 2003 ; 111 : 453-61.
38. Senno M, Menghini R, Fiorentino L, et al. TNF-alpha converting enzyme heterozygous mice are protected from obesity-induced insulin resistance and diabetes. Diabetes 2007 ; 56 : 2541-6.
39. Togashi N, Ura N, Higashiura K, et al. Effect of TNF-(alpha)-converting enzyme inhibitor on insulin resistance in fructose-fed rats. Hypertension 2002 ; 39 : 578-80.
40. Gelling RW, Yan W, Al-Noori S, et al. Deficiency of TNF(alpha) converting enzyme (TACE/ADAM17) couses a lean, hypermetabolic phenotype in mice. Endocrinology 2008 ; 149 : 6053-64.
41. Federici M, Hribal ML, Menghini R, et al. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 2005 ; 115 : 3494-505.
42. Moss ML, Sklair-Tavron L, Nudelman R. Drug insight : tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 2008 ; 4 : 300-9.
43. Surena AL, de Faria GP, Studler JM, et al. DLG1/SAP97 modulates transforming growth factor alpha bioavailability. Biochim Biophys Acta 2008, 27 septembre online.